Literature DB >> 17040113

Combination therapy in epilepsy: when and what to use.

Patrick Kwan1, Martin J Brodie.   

Abstract

After being regarded as a last resort for over two decades, the role of combination therapy as a treatment strategy for epilepsy is undergoing re-evaluation. This is a result of the growing appreciation that all seizures cannot be controlled by monotherapy in a substantial proportion of patients, and of the development of a range of modern antiepileptic drugs (AEDs), some of which are better tolerated and less prone to complex pharmacokinetic drug interactions than their older counterparts.Robust evidence to guide clinicians on when and how to combine AEDs is lacking, and current practice recommendations are largely empirical. Monotherapy should remain the treatment of choice for newly diagnosed epilepsy. A combination of two AEDs can be considered after failure, resulting from lack of efficacy, of one or two different monotherapy regimens. A few patients will become seizure-free with a combination of three AEDs, but treatment with a combination of four or more is unlikely to be successful. There is some evidence to support a pharmacomechanistic approach to AED combination. Care should be taken to avoid excessive drug load, which is associated with increased toxicity. Bigger and better randomised, controlled studies are needed to determine the optimal time and way to combine AEDs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17040113     DOI: 10.2165/00003495-200666140-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  63 in total

1.  Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?

Authors:  F M Besag; D J Berry; F Pool; J E Newbery; B Subel
Journal:  Epilepsia       Date:  1998-02       Impact factor: 5.864

2.  The new antiepileptic drugs: a systematic review of their efficacy and tolerability.

Authors:  A G Marson; Z A Kadir; J L Hutton; D W Chadwick
Journal:  Epilepsia       Date:  1997-08       Impact factor: 5.864

3.  Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study group.

Authors:  M J Brodie; J P Mumford
Journal:  Epilepsy Res       Date:  1999-04       Impact factor: 3.045

4.  The efficacy of carbamazepine combinations in epilepsy.

Authors:  J J Cereghino; J T Brock; J C Van Meter; J K Penry; L D Smith; B G White
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

5.  Effectiveness of first antiepileptic drug.

Authors:  P Kwan; M J Brodie
Journal:  Epilepsia       Date:  2001-10       Impact factor: 5.864

Review 6.  Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy.

Authors:  Patrick Kwan; Martin J Brodie
Journal:  Neurology       Date:  2003-06-10       Impact factor: 9.910

7.  Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment.

Authors:  M W Lammers; Y A Hekster; A Keyser; H Meinardi; W O Renier; H van Lier
Journal:  Epilepsia       Date:  1995-05       Impact factor: 5.864

8.  One drug (phenytoin) in the treatment of epilepsy.

Authors:  E H Reynolds; D Chadwick; A W Galbraith
Journal:  Lancet       Date:  1976-05-01       Impact factor: 79.321

Review 9.  Overtreatment in adults with epilepsy.

Authors:  Charles L P Deckers
Journal:  Epilepsy Res       Date:  2002-11       Impact factor: 3.045

10.  Drug treatment of epilepsy: when does it fail and how to optimize its use?

Authors:  Patrick Kwan; Martin J Brodie
Journal:  CNS Spectr       Date:  2004-02       Impact factor: 3.790

View more
  29 in total

1.  A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs.

Authors:  John-Kenneth Sake; David Hebert; Jouko Isojärvi; Pamela Doty; Marc De Backer; Kendra Davies; Andrea Eggert-Formella; James Zackheim
Journal:  CNS Drugs       Date:  2010-12       Impact factor: 5.749

2.  Effect of minocycline on pentylenetetrazol-induced chemical kindled seizures in mice.

Authors:  Nooshin Ahmadirad; Amir Shojaei; Mohammad Javan; Mohammad H Pourgholami; Javad Mirnajafi-Zadeh
Journal:  Neurol Sci       Date:  2013-10-15       Impact factor: 3.307

3.  Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study.

Authors:  Zhibin Chen; Martin J Brodie; Danny Liew; Patrick Kwan
Journal:  JAMA Neurol       Date:  2018-03-01       Impact factor: 18.302

Review 4.  Pharmacological Treatment of Drug-Resistant Epilepsy in Adults: a Practical Guide.

Authors:  Martin J Brodie
Journal:  Curr Neurol Neurosci Rep       Date:  2016-09       Impact factor: 5.081

5.  Isobolographic Analysis of Antiseizure Activity of the GABA Type A Receptor-Modulating Synthetic Neurosteroids Brexanolone and Ganaxolone with Tiagabine and Midazolam.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2019-12-16       Impact factor: 4.030

6.  Epilepsy and nonlinear dynamics.

Authors:  Klaus Lehnertz
Journal:  J Biol Phys       Date:  2008-07-09       Impact factor: 1.365

7.  [Anticonvulsant add-on therapy with Eslicarbazepine acetate : Results of the EPOS-study in adults in Germany].

Authors:  F-P Losch; M Holtkamp; R McMurray; D Lendemans; E Kockelmann
Journal:  Nervenarzt       Date:  2016-10       Impact factor: 1.214

8.  Correlation between prescribed daily dose, seizure freedom and defined daily dose in antiepileptic drug treatment.

Authors:  László Horváth; Klára Fekete; Sándor Márton; István Fekete
Journal:  Int J Clin Pharm       Date:  2017-03-02

9.  Efficacy of topiramate in adult patients with symptomatic epilepsy: an open-label, long-term, retrospective observation.

Authors:  Yang Lu; Weihua Yu; Xuefeng Wang
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 10.  Selecting Rational Drug Combinations in Epilepsy.

Authors:  Bassel Abou-Khalil
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.